RELEASE: GenSci launches global innovation center in Shanghai

(Information sent by the signatory company).

RELEASE: GenSci launches global innovation center in Shanghai

(Information sent by the signatory company)

The establishment of the center demonstrates the company's commitment to offering differentiated solutions to the challenges of gynecology and pediatrics.

SHANGHAI, Dec. 26, 2023 /PRNewswire/ -- Changchun GeneScience Pharmaceutical ("GenSci"), a subsidiary of Changchun High-Tech Industries (Group), hosted an opening ceremony for its new global headquarters and research and development center ( L D) at Shanghai Zhangjiang International Medical Park on December 15. This facility is on track to be fully operational in 2027, with the capacity to house 2,000 R&D professionals.

Since its founding in 1997, GenSci has introduced several innovative therapies, including GenSci recombinant human growth hormone, GenSci Heng recombinant human follicle-stimulating hormone, and Jinfuning recombinant human granulocyte-stimulating factor gel.

Understanding the crucial role of women's and children's health in the nation's overall well-being, with a continued focus on growth disorders in children, GenSci has expanded its attention to the broader spectrum of children's health. This includes addressing concerns such as abnormal sexual development, obesity, respiratory and digestive health, allergies and autoimmune disorders, neurological and speech development, as well as body image concerns.

GenSci, through a combination of proprietary research and development and collaborative efforts with partners, has developed a set of sophisticated research and development technology platforms that drive forward-thinking product development. The platforms focus on sustained release technology for protein drugs, mucosal delivery systems for nucleic acid drugs, antibody-drug conjugate (ADC) technology, and innovations in ultrasound and hydrogel technologies.

GenSci has increased its R&D investments to address the unmet health needs of women and children. The company has already developed the ability to innovate in several product categories, including biopharmaceuticals, chemical drugs, live bacterial preparations (LBPs) and medical devices.

"GenSci has created an innovative and globally competitive R&D product portfolio," said Dr. Jin Lei, Chief Scientist and CEO of GenSci. "By 2025, the company will have a broad pipeline, expecting to launch more than four breakthrough first-in-class medicines and five novel medical devices annually in the coming years."

The establishment of the R&D center lays the foundation for GenSci to further advance the convergence of industry, academia, research and the medical community. Leveraging cutting-edge research and development capabilities and the application of artificial intelligence technologies, GenSci is well positioned to provide premium health solutions for women and children. The initiative aligns with GenSci's commitment to harnessing science and technology to protect and improve the health of these vulnerable groups.


View original content: